SURGE IN MEDICINES

SURGE IN MEDICINES PRICES FOR TREATMENT OF DEADLY DISEASES

03 Apr, 2019

ISLAMABAD (9 News) – Pharmaceutical companies have increased 45 per cent prices of various medicines including the life-savings drugs.

The incumbent government, which claims to have betterment for the poor, even snatched the poor’s rights for treatment of their disease.

Following devaluation of the local currency and stringent Drug Regulatory Authority of Pakistan (DRAP) regulations, the medicines for the treatment of potentially deadly diseases have also been surged by Rs399.

It was reported that the price hike would impact the rate of many medicines, including the life-savings drugs such as medicines for heart ailments, brain diseases, cancer, children’s diseases and post-surgical drugs etc.

It also said that the price of Triforge, a medicine for heart ailment, has been increased from Rs186 to Rs485, and the price of a medicine for controlling blood sugar has been increased from the previous Rs272 to Rs460.

Meanwhile, the price of Erythrosine, a medicine for the treatment of throat-related diseases, has been increased from Rs548 to Rs921.

Moreover, the price of Concor, a medicine for the treatment of blood pressure, has been raised from Rs162 to Rs235. The cost of Disprin has been increased by Rs27.

DRAP increases prices of medicines from 9 to 15 per cent

Earlier, the Drug Regulatory Authority of Pakistan (DRAP) announced a price hike of medicines from 9 to 15 percent across the country.

The DRAP issued a notification of hike in prices of drugs. The notification stated that the revised maximum retail prices of the medicines will be printed on the label.

Drug companies had been demanding an increase in the prices of medicines for some time. The companies had also threatened to stop manufacturing drugs.

 

DRAP, accepting the drug manufacturers’ demands, issued a notification for the increase in medicine prices.

According to the notification:

1.Maximum retail prices of drugs may be increased under paragraph 12 (8) of Drug Pricing Policy, 2018, namely:

(a) “Nine percent over and above the maximum retail prices determined as determined under hardship category during the year 2018; and

(b) Fifteen percent over and above existing maximum retail prices determined under the Drug Pricing Policy, 2018 for drugs other than those specified in clause (a)

2.The revised maximum retail prices shall be printed on the label in the manner prescribed by the Drugs [Labelling and Packaging] Rules, 1986 and the manufacturers and importers of drugs shall furnish calculations of revised maximum retail price of drugs to the Division of Costing and Pricing of the Drug Regulatory Authority of Pakistan before affecting the increase.

On the other hand, the consumers demanded from the government to review this decision. A consumer told 92 News that the poor’s survival become very difficult in this scenario.